Monopar Therapeutics Inc. - MNPR STOCK NEWS

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced positive early data from its ongoing MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial, validating the tumor targeting ability of MNPR-101-Zr in humans. The trial focuses on MNPR-101, a proprietary first-in-class humanized monoclonal antibody targeting cancers expressing the urokinase plasminogen activator receptor (uPAR).

Key findings include:

• Highly preferential uptake of MNPR-101-Zr in metastatic tumors relative to normal tissue
• Specificity and durability of MNPR-101-Zr in tumor targeting
• Alignment of MNPR-101-Zr uptake with previously observed metastatic tumors on FDG PET imaging

Monopar also received clearance in Australia to initiate an MNPR-101-Lu Phase 1 therapeutic clinical trial, scheduled for Q4 2024. Additional data will be presented at the European Association of Nuclear Medicine 2024 Annual Congress in October.

Monopar Therapeutics (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative cancer treatments, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Chandler D. Robinson, MD, Monopar's CEO, will present at the conference. Key details include:

• Presentation will be webcast starting Monday, September 9, 2024 at 7:00 a.m. ET
• In-person one-on-one meetings will be held at the Lotte New York Palace, NY
• Conference dates: September 9 - 11, 2024

This event provides Monopar an opportunity to showcase its progress and connect with potential investors, potentially impacting its stock performance (MNPR).

Monopar Therapeutics (Nasdaq: MNPR), a clinical-stage radiopharma company, has regained compliance with Nasdaq's minimum bid price requirement. The company received notice from Nasdaq that it has met the listing rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for at least 10 consecutive trading sessions. This development ensures Monopar's continued listing on the Nasdaq stock exchange, maintaining its visibility and access to capital markets. The compliance status is important for the company's ongoing efforts in developing innovative cancer treatments.

Monopar Therapeutics Inc. (Nasdaq: MNPR) has received Human Research Ethics Committee (HREC) clearance in Australia to begin a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu. This treatment combines lutetium-177 with Monopar's proprietary humanized monoclonal antibody MNPR-101, which targets the urokinase plasminogen activator receptor (uPAR). The trial will enroll patients with advanced solid cancers and follows the ongoing MNPR-101-Zr imaging and dosimetry clinical trial.

Preclinical studies have shown promising results, with MNPR-101-Lu demonstrating durable antitumor effects in a human pancreatic cancer xenograft mouse model. The treatment achieved complete tumor elimination after a single injection, lasting throughout the 90-day study. Imaging data also revealed high specificity and durable uptake of MNPR-101-Lu in tumors relative to normal tissue.

Monopar Therapeutics Inc. (Nasdaq: MNPR) has announced initial data from the first patient dosed in its Phase 1 clinical trial of MNPR-101-Zr, a uPAR-targeted imaging radiopharmaceutical. The drug was well-tolerated with no serious adverse reactions reported. Preliminary analysis suggests low radiation dose to healthy tissue, aligning with preclinical data. Dosimetry analysis showed absorbed organ doses well below accepted safety limits, with red bone marrow radiation dose about 150 times less than the generally accepted limit. No unanticipated or excessive uptake was observed in critical organs. The study aims to include patients with cancers known for high uPAR expression to gain insight into MNPR-101-Zr's tumor uptake profile.

Monopar Therapeutics Inc. (Nasdaq: MNPR) reported its Q2 2024 financial results and recent developments. Key highlights include:

1. Initiated and enrolling patients in MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial.

2. MNPR-101 radio-immuno-therapeutic (RIT) Clinical Trial on track to start in Q4 2024.

3. Cash position of $7.1 million as of June 30, 2024, sufficient to operate through August 31, 2025.

4. Net loss of $1.7 million ($0.10 per share) in Q2 2024, compared to $2.2 million ($0.16 per share) in Q2 2023.

5. R&D expenses decreased to $1,131,000 in Q2 2024 from $1,595,000 in Q2 2023.

6. G&A expenses decreased to $658,000 in Q2 2024 from $733,000 in Q2 2023.

7. Approved 1-for-5 reverse stock split, effective August 12, 2024, to regain Nasdaq compliance.

Monopar Therapeutics (Nasdaq: MNPR) has announced a 1-for-5 reverse stock split of its common stock, effective August 12, 2024. The split aims to regain compliance with Nasdaq's listing rules. Trading on a split-adjusted basis will begin on August 13, 2024, under the new CUSIP number 61023L207. The reverse split will reduce outstanding shares from approximately 17.6 million to 3.5 million. Stockholders' ownership percentages will remain unchanged, except for adjustments due to fractional shares. The split will not affect the number of authorized shares or par value. VStock Transfer will manage the exchange process for physical share certificates, while book-entry holders need not take action.

Monopar Therapeutics (Nasdaq: MNPR) has enrolled the first patient in its first-in-human Phase 1 trial for MNPR-101-Zr, a novel radiopharmaceutical imaging agent. This agent combines Monopar's antibody, MNPR-101, which targets the urokinase plasminogen activator receptor (uPAR) with the radioisotope zirconium-89. The trial, led by Prof. Rodney Hicks at the Melbourne Theranostic Innovation Centre, aims to assess the safety and dosimetry in up to 12 patients with advanced cancers. uPAR is a target in aggressive cancers such as pancreatic, triple-negative breast, and colorectal cancers. Preclinical results have been promising.

Monopar Therapeutics (Nasdaq: MNPR) has announced that their abstract on MNPR-101-RIT has been selected as a top-rated oral presentation at the European Association of Nuclear Medicine (EANM) 2024 Annual Congress in Hamburg, Germany. The abstract showcases preclinical data on MNPR-101-RIT, a novel radio-immuno-therapeutic targeting urokinase plasminogen activator receptor (uPAR) for treating cancers such as triple-negative breast, colorectal, and pancreatic. The data highlights significant anti-tumor benefits using therapeutic radioisotopes Lutetium-177 and Actinium-225. Additionally, Monopar has started a Phase 1 clinical trial for MNPR-101-Zr in advanced cancer patients.